MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.29

21 Sep
2021

0.010

OPEN

$0.28

3.57%

HIGH

$0.30

3,302,930

LOW

$0.28

TARGET
$0.307 5.7% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . CSL . IDT . IVX . MSB . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . OPT . ANP .
FNARENA'S MARKET CONSENSUS FORECASTS
MYX: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 13.3 - 1.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-13.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx400.8 M
Book Value Per Share xxxxxxxxxxxxxxx43.5
Net Operating Cash Flow xxxxxxxxxxxxxxx47.3 M
Net Profit Margin xxxxxxxxxxxxxxx-52.00 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx-12.55 %
Return on Equity xxxxxxxxxxxxxxx-23.08 %
Return on Total Capital xxxxxxxxxxxxxxx0.11 %
Capex xxxxxxxxxxxxxxx25.1 M
Capex % of Sales xxxxxxxxxxxxxxx6.26 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx30.2 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

30/08/2021

1

Upgrade to Buy from Neutral

$0.35

20.69%

Mayne Pharma is in a transition phase, Citi notes, moving from being dominated by generic drug revenue to branded products being
the company's largest segment. To that end FY22 guidance includes a big step-up in the cost of the launch of Nextstellis.

In the meantime, generic revenues will likely continue to fall, while Nextstellis should make a loss until revenues become meaningful. The launch is not without significant risk, the broker warns.

Target falls to 35c from 43c but on the stock market reaction Citi upgrades to Buy (High Risk)  from Neutral.

FORECAST
Citi forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -0.50 cents.
Citi forecasts a full year FY23 dividend of 0.00 cents and EPS of 1.90 cents.

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

MYX STOCK CHART